African Global Pharma Delays Ghana Manufacturing Facility Test Runs to Complete World Health Organization (WHO) Standards

   Emerging World Pharma Inc. (PINKSHEETS: EWPI) -- After discussions with the Food and Drug Board Ghana (FDB), test runs expected to start in May have been pushed back 45 days. African Global Pharma will delay test runs in order to bring the facility up to manufacturing standards set by the World Health Organization (WHO).

Emerging World Pharma president, Mr. Brandon Keks, noted," By no means do we consider this an actual delay. By completing these upgrades, African Global Pharma will be able to increase their capabilities for producing a wider range of products and intends to produce generic pharmaceutical products that will have certification to be marketed and sold globally. While taking these measures now, AGP believes it has saved a considerable amount of expense and avoided future delays in production."

By complying to these manufacturing standards, WHO certification will also allow African Global Pharma to be eligible for various grants and funding.

Emerging World Pharma continues to explore further opportunities within the West African markets of Benin and Nigeria.

www.emergingpharma.com

About Emerging World Pharma Inc.

Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.

The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups: church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact: Joel Everret Emerging World Pharma Inc. Investor Relations Division 703-646-2633 Email: [e-mail]